23/12/2009
CSL Limited and National Blood Authority sign new Australian Fractionation Agreement
CSL Limited (ASX: CSL) announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products. More.

08/12/2009
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years. More.

19/08/2009
Full-year results for 2008/09
CSL Limited today announced a profit after tax of $1.15 billion for the twelve months ended 30 June 2009, up 63% when compared to the twelve months ended 30 June 2008. More.

>> Prior ASX Releases

Investors Contact

Mark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
Email: mark.dehring@csl.com.au
45 Poplar Rd
Parkville
Victoria 3052
Australia

Privacy | Terms of Use | Employees | Webmaster